3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
19
Head & Neck
7
Genitourinary
7
Gastrointestinal
7
Dermatologic
7
Thoracic
5
Breast
4
Lymphoid
2
Other solid neoplasm
1
Conditions
Solid Tumors
11
Mesothelioma, Malignant
8
Solid Tumor
6
Advanced Solid Tumor
6
Mesothelioma
3
Melanoma
3
Carcinoma, Renal Cell
3
Carcinoma, Non-Small-Cell Lung
3
Advanced Solid Tumors
3
Treatment-Refractory Solid Tumors
2
Squamous Cell Carcinoma of Head and Neck
2
Carcinoma, Merkel Cell
2
Wilms Tumor
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thoracic Neoplasms
1
Stomach Neoplasms
1
Solid Tumour
1
Solid Tumor, Adult
1
Small Cell Lung Carcinoma
1
Select Advanced Solid Tumors
1
Nasopharyngeal Neoplasms
1
Nasopharyngeal Carcinoma
1
Locally Advanced or Metastatic Solid Tumors
1
Locally Advanced Solid Tumors
1
Locally Advanced Solid Tumor
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
HER2-positive Breast Cancer
1
Gastrointestinal Neoplasms
1
Interventions
pembrolizumab
8
Nivolumab
3
tislelizumab
2
spartalizumab
2
SS1(dsFv)PE38
2
Ipilimumab
2
fludarabine phosphate
1
fludarabine
1
epacadostat
1
entinostat
1
bosutinib
1
atezolizumab
1
aldesleukin
1
Quality of Life
1
Polymerase Chain Reaction
1
Platinum
1
Pemetrexed
1
Patient Reported Outcome Measures
1
Paclitaxel
1
Molecular Diagnostic Techniques
1
Microarray Analysis
1
Interleukin-2
1
Immunotherapy
1
Immunoenzyme Techniques
1
Hyperthermic Intraperitoneal Chemotherapy
1
Gene Expression Profiling
1
Gemcitabine
1
Flow Cytometry
1
Fentanyl
1
Erlotinib Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uterine Cervical Neoplasms
×
atezolizumab
×
Other solid neoplasm
×
Clear all
NCT06444815
2026-04-07
STEALTH-001
KaliVir Immunotherapeutics
Phase 1
Recruiting
60 enrolled